Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ninja-forms domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home4/canaafor/public_html/wp-includes/functions.php on line 6114
Research - Canadian Alopecia Areata Foundation

Research Articles

Research2022-04-19T16:30:19+00:00

Long Term use of JAK Inhibitors (CTP-543) Shows Promising Results In CoNCERT Pharmaceuticals Study

Long Term use of JAK Inhibitors (CTP-543) Shows Promising Results In CoNCERT Pharmaceuticals Study Anthony Gilding, Science Communication at CANAAF CANAAF is very pleased to announce this exciting data presented by CoNCERT Pharmaceuticals at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The data showed that, as with the previous

November 4th, 2020|

Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study

Alopecia Areata is a particularly distressing condition. The hair loss faced by patients is unexpected, and often rapid, leaving them feeling hopeless and vulnerable. Given how much we associate our identity with how we look, patients often feel that they have lost their sense of identity when they lose their hair.    Though the

October 23rd, 2020|

Journals with Alopecia Research

For those of you looking for scientific updates, here are a list of journals that publish alopecia research. Journal of the American Academy of Dermatology Journal of the American Medical Association - Dermatology Dermatologic Therapy Journal of Investigative Dermatology   The New England Journal of Medicine    Journal of Dermatological Science    Australasian Journal

September 23rd, 2020|

Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata

On September 1st, 2020, Arena Pharmaceuticals announced that the first subject has been dosed in Phase 2 of their trial evaluating a drug called Etrasimod, a Sphingosine-1-phosphate (S1P) Receptor Modulator for the treatment of moderate-to-severe Alopecia Areata. This clinical trial is a randomized, placebo-controlled trial, meaning that 36 subjects will be chosen randomly to

September 9th, 2020|

CSPA Survey: Access to Dermatology Care

The Canadian Skin Patient Alliance (CSPA) is conducting a survey on the impact of COVID-19 on access to dermatology care. Please take a moment to fill out the survey by clicking the link below: Take Survey Learn more by visiting the CSPA website and Facebook page.

August 27th, 2020|

Research Articles on Healthcare Inequalities in Canada

CANAAF stand with the Black community in the fight against anti-Black racism! #BlackLivesMatter! Minority populations, especially Black and Indigenous communities, are likely to experience poorer healthcare and health outcomes in Canada. These disparities in healthcare can lead to differences in the risk of developing many conditions, including Alopecia Areata. Below are a few articles

August 7th, 2020|
Watch Alopecia Areata Research Update 2020

Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.

Go to Top